Trial Profile
Effects of BMS-986142 on the Single-dose Pharmacokinetics of Methotrexate and Probe Substrates Montelukast (CYP2C8), Flurbiprofen (CYP2C9), Midazolam (CYP3A4), Digoxin (P-gp), and Pravastatin (OATP1B1) in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs BMS 986142 (Primary) ; Digoxin; Flurbiprofen; Folinic acid; Methotrexate; Midazolam; Montelukast; Pravastatin
- Indications Rheumatoid arthritis
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 06 Mar 2017 Results (n=12) assessing effect of BMS-986142 on the PK of methotrexate, published in the European Journal of Clinical Pharmacology
- 29 Jan 2016 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov record.
- 02 Jun 2015 New trial record